Weight-loss drugs like Ozempic have so much promise a major bank is telling investors to short junk food stocks

a picture of four wegovy injections (Credit: Michael Siluk—UCG/Universal Images Group/Getty Images)

It didn’t take much for Novo Nordisk’s “miracle” drugs Ozempic and Wegovy to surge in popularity—after all, they presented a safe path to shed weight while, in fact, reducing some health risks. 

Now, major British bank Barclays is predicting the impact and potential uptake of such drugs to be so substantial that it’s recommending that investors short stocks that are targeted by the weight-loss drug industry—including junk food and cigarette companies.